TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19439284
Drug: Uterine cavity
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer
Study: 18308656
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin regimen (0.5 U/kg total daily dose: 0.25 U/kg insulin glargine and 0.25 U/kg divided into 3 mealtime doses)
Study: 15026400
Drug: Iontophoretic fentanyl
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Iontophoretic fentanyl hydrochloride (40-microg infusion over 10 minutes)
Study: 15026400
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h)
Study: 11393871
Drug: Prison-based residential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prison-based residential drug treatment
Study: 26941050
Drug: ECIG with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECIG with 0 mg/ml nicotine concentration
Study: 26941050
Drug: ECIG with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECIG with 8 mg/ml nicotine concentration
Study: 26941050
Drug: ECIG with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECIG with 36 mg/ml nicotine concentration
Study: 26941050
Drug: All ECIG
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All ECIG conditions (0, 8, 36 mg/ml)
Study: 10772502
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline 500 mg administered 45 minutes prior to SWL
Study: 3537248
Drug: Vaccine virus
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine virus at 10(7) TCID50/ml
Study: 3537248
Drug: Vaccine virus
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine virus at 10(8) TCID50/ml
Study: 3537248
Drug: Both vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccine groups (10(7) and 10(8) TCID50/ml)
Study: 27992863
Drug: Statin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin plus fenofibrate treatment in patients without CKD
Study: 27992863
Drug: Statin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin plus fenofibrate treatment in patients with CKD
Study: 25611084
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg QW plus topical therapies
Study: 23224792
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once a day, rabeprazole 20 mg twice a day, and tinidazole 500 mg twice daily for 7 days followed by rabeprazole 20 mg OD for 8 weeks
Study: 18495885
Drug: Glutamate antagonists
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate antagonists (caroverine and ketamine) administered during sleep
Study: 9170519
Drug: Low-dose MPA
Normalized name: chitosan low molecular weight (20-200 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose MPA (600 mg/day)
Study: 9170519
Drug: High-dose MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MPA (1,200 mg/day)
Study: 8253229
Drug: Intermittent pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent pilocarpine drop medication (2%)
Study: 8253229
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose pilocarpine delivery by a membrane-controlled Ocusert unit (P40)
Study: 31324831
Drug: Dobutamine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (5, 10, 20 μg/kg.min)
Study: 29068453
Drug: SFA high‐fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFA high‐fat meal with orange juice (500 ml)
Study: 29068453
Drug: MUFA high‐fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUFA high‐fat meal with orange juice (500 ml)
Study: 22994024
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml (Group I)
Study: 22994024
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg (Group II)
Study: 22994024
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (Group III)
Study: 10929726
Drug: Standardized pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized pain therapy with tramadol and diclofenac
Study: 10929726
Drug: No standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: No standardized pain therapy
Study: 8523873
Drug: Duraflo II
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraflo II heparin-treated circuits
Study: 1742223
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (FA) + 5-fluorouracil (5-FU) (200 mg/sqm i.v. x 5 days + 400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Study: 1742223
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) alone (400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Study: 6972018
Drug: Triple sulfa
Normalized name: Triple Sulfa
DrugBank: Sulfabenzamide (DB09355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple sulfa cream
Study: 26304886
Drug: Lenalidomide alone
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide alone (15 mg per day on days 1 to 21, followed by 7 days of rest in cycle 1; then 20 mg per day on days 1 to 21, followed by 7 days of rest in cycles 2 to 12)
Study: 26304886
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus Rituximab (LR) (Rituximab 375 mg/m2 weekly for 4 weeks; Lenalidomide as above)
Study: 15562056
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine 1.5 mg/kg
Study: 11352682
Drug: Serum elastin
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum elastin peptides (EP) and procollagen‐IIIN‐terminal propeptide (PIIINP) measured in ng/ml using ELISA and RIA techniques.
Study: 9135021
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with 5-fluorouracil plus levamisole
Study: 7523647
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (12.8 mg iron per liter)
Study: 7523647
Drug: Regular formula
Normalized name: COMPLEAT REGULAR FORMULA LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular formula (1.1 mg iron per liter)
Study: 31836609
Drug: Capivasertib 480
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib 480 mg b.i.d.
Study: 31836609
Drug: Capivasertib 360
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib 360 mg b.i.d.
Study: 31836609
Drug: Capivasertib 240
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib 240 mg b.i.d.
Study: 17132769
Drug: Daily sunscreen
Normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sunscreen use
Study: 12843357
Drug: Common haplotype
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common haplotype A-G-8/12-C
Study: 10068383
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus daily MPA
Study: 1704026
Drug: Cold glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold glucose solution (5 degrees C)
Study: 1704026
Drug: Warm glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm glucose solution (50 degrees C)
Study: 6660202
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Reha of the lesion with acupuncture on the abnormal side (including points Chu‐chih (LI‐11), Shou‐san‐li (LI‐10), Wai‐kuan (TH‐5), Ho‐ku (LI‐4), Yang‐chih (TH‐4)).
Study: 6660202
Drug: Simple treatment
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple treatment with Reha on the abnormal side.
Study: 6660202
Drug: Simple treatment
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple treatment with acupuncture on the abnormal side.
Study: 30037491
Drug: CPT‐11 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 (irinotecan hydrochloride) administered at a dosage of 100 mg/m2 via intravenous infusion on days 1, 8, and 15 of a 4-week cycle, for up to 2 cycles.
Study: 22433300
Drug: Flurbiprofen 8.75-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75-mg lozenges (test drug)
Study: 22433300
Drug: Flurbiprofen 8.75-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75-mg lozenges (reference drug)
Study: 20694731
Drug: Cooling collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling collar (CC(90))
Study: 20694731
Drug: Cooling collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling collar (CC(15))
Study: 17987285
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg once on the first day and 200 mg once on the second day)
Study: 17987285
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 microg/kg of intravenous fentanyl without pretreatment)
Study: 12391036
Drug: Coffee ingestion
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee ingestion (5 mg caffeine/kg body mass)
Study: 9135468
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide administered 90 min prior to barium
Study: 1398229
Drug: Psyllium (10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (10.8 g)
Study: 22633178
Drug: Educational and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational and environmental intervention (weekly nutrition and food classes and food environment changes)
Study: 20045366
Drug: Miglustat (Zavesca)
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Miglustat (Zavesca) for >or= 1 dose
Study: 15974563
Drug: etoricoxib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib (60 mg, 90 mg, or 120 mg)
Study: 15974563
Drug: non-selective NSAIDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-selective NSAIDs (ibuprofen, diclofenac, or naproxen)
Study: 11379456
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of the TSI-GSD 200 vaccine
Study: 11379456
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two doses of the TSI-GSD 200 vaccine
Study: 1531259
Drug: Phloroglucinol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol (40 mg, two ampoules)
Study: 31489020
Drug: Oral Labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Labetalol
Study: 31489020
Drug: Oral Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Nifedipine
Study: 24778393
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28)
Study: 20086031
Drug: Linagliptin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (10 mg, oral)
Study: 20086031
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg, intravenous)
Study: 18955380
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of iron
Study: 18955380
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of desferrioxamine
Study: 15468991
Drug: L-sulpiride (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-sulpiride (25 mg t.i.d. intravenously for 3 days, then orally for 7 days)
Study: 8310852
Drug: L-sulpiride
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-sulpiride
Study: 7663466
Drug: Implant design,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant design, application, and site of placement
Study: 3604933
Drug: Sonicated Renografin‐76
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonicated Renografin‐76 (1.5 to 2.0 ml)
Study: 3604933
Drug: Nonsonicated Renografin‐76
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsonicated Renografin‐76 (7 to 9 ml)
Study: 25246774
Drug: Aminaphtone (Capilarema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminaphtone (Capilarema 75 mg) administered twice daily for 5 days
Study: 25246774
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 5 days
Study: 22047100
Drug: Errorless naming
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Errorless naming treatment (ENT)
Study: 19283886
Drug: HP-L (High
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-L (High Protein at Lunch)
Study: 17375492
Drug: Intervention dose
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention dose (number of six possible intervention components completed)
Study: 11916546
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days)
Study: 11916546
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days) plus alpha-interferon 2b (3 million Units/day subcutaneously from day 1 for 5 days)
Study: 7630152
Drug: Ibopamine 100
Normalized name: ibopamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 100 mg orally (p.o.)
Study: 2705719
Drug: PTFE (Gore‐tex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE (Gore‐tex, W L Gore)
Study: 937355
Drug: Meperidine hydrochloride
Normalized name: Meperidine Hydrochloride
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine hydrochloride 100 mg
Study: 937355
Drug: Pentazocine 60
Normalized name: pentazocine 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 60 mg
Study: 25299740
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel filler augmentation of the tear trough
Study: 25299740
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel augmentation of the cheek
Study: 11532487
Drug: Intergel solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intergel solution (300 mL)
Study: 9448656
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (100‐300 mg/day)
Study: 11910265
Drug: Sertraline (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50‐200 mg/day)
Study: 7939468
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist (Zoladex)
Study: 3374415
Drug: Continuing medical
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing medical education (CME) in cardiovascular and cancer medicine
Study: 29331663
Drug: Mitomycin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin (40 mg)
Study: 31720933
Drug: Oxaliplatin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (200 mg/m2)
Study: 31666152
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (0.2 mg) IN SCOP
Study: 31666152
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (0.4 mg) IN SCOP
Study: 21742071
Drug: ronacaleret 200
Normalized name: Ronacaleret
DrugBank: Ronacaleret (DB05255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ronacaleret 200 mg twice daily
Study: 21742071
Drug: ronacaleret 400
Normalized name: Ronacaleret
DrugBank: Ronacaleret (DB05255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ronacaleret 400 mg once daily
Study: 19445553
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg and paracetamol 325 mg up to 8 hourly for >/= 6 weeks (group A)
Study: 19445553
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg and paracetamol 325 mg up to 8 hourly for >/= 6 weeks (group B)
Study: 19445553
Drug: Oxycodone/paracetamol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/paracetamol therapy (group B)
Study: 19445553
Drug: Oxycodone/paracetamol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/paracetamol therapy (both groups)
Study: 16778460
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of the agents
Study: 11787984
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg iron daily (enriched with Zn, Cu, Se, vitamin B12, and folate)
Study: 11787984
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15 mg iron)
Study: 3291161
Drug: RT following
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT following chemotherapy
Study: 3291161
Drug: RT following
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT following low dose concurrent irradiation with chemotherapy (LDC‐RT)
Study: 3291161
Drug: RT concurrently
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT concurrently used with chemotherapy
Study: 27765707
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy (initiated within 28 days of the index visit)
Study: 27765707
Drug: No early
Approvals — FDA: no, EMA: no, PMDA: no
Description: No early physical therapy
Study: 25487817
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with cilostazol and aspirin or clopidogrel
Study: 25487817
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or clopidogrel monotherapy
Study: 25487817
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with cilostazol and aspirin
Study: 22073891
Drug: Warm acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm acupuncture combined with intra-articular injection of sodium hyaluronate
Study: 22073891
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intra-articular injection of sodium hyaluronate only)
Study: 15285333
Drug: Daonil tablets
Normalized name: Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daonil tablets (Hoechst)
Study: 12738722
Drug: Erythropoietin (r‐HuEpo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (r‐HuEpo) 40,000 IU s.c. once weekly
Study: 10957752
Drug: Estrogen alone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen alone or in combination with progestogens
Study: 1308305
Drug: Midazolam (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.10 mg/kg)
Study: 3497885
Drug: Co-trimoxazole suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole suspension alone
Study: 3497885
Drug: Co-trimoxazole suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole suspension with pectin-kaolin
Study: 30377210
Drug: Rose geranium
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL SPRAY [All Good Rose Geranium Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rose geranium nasal spray
Study: 29208831
Drug: Trypan blue
Normalized name: Trypan Blue
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trypan blue dye (0.06%) irrigation in the capsular bag, 0.2 ml injected after cortical cleanup under air.
Study: 29208831
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution, 0.2 ml injected in a similar manner as the dye group.
Study: 29208831
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution.
Study: 22018129
Drug: Gynol II
Normalized name: Gynol II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynol II vaginal gel
Study: 22018129
Drug: Hydroxyethyl cellulose
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl cellulose gel (HEC)
Study: 22018129
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel exposure
Study: 12588271
Drug: Digoxin (SDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (SDC 0.5-0.8 ng/mL, n = 572)
Study: 12588271
Drug: Digoxin (SDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (SDC 0.9-1.1 ng/mL, n = 322)
Study: 12588271
Drug: Digoxin (SDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (SDC >=1.2 ng/mL, n = 277)
Study: 9398695
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta‐estradiol (2 mg/day)
Study: 31073087
Drug: Domiciliary oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary oxygen therapy (DOXT)
Study: 16729780
Drug: Roflumilast (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast (all doses)